CGEN News Alert Compugen Ltd (CGEN) 8.27 12/13/2014 00:34:11

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 1:34 AM

Compugen Ltd (CGEN) 8.27 $CGEN

Will Compugen (CGEN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:39AM CST
Will Compugen (CGEN) Continue to Surge Higher?
CGEN: 8.27 (+0.14)

Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:25AM CST
Compugen (CGEN) was a big mover last session, with shares rising nearly 9% on the day.
BIIB: 344.49 (+2.16), ANIP: 54.28 (+2.33), CGEN: 8.27 (+0.14), AFFX: 8.94 (-0.36)

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 344.49 (+2.16), GILD: 104.13 (-0.18), CGEN: 8.27 (+0.14), ASPX: 24.90 (+0.64), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93)

Compugen to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Dec 03, 6:01AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Office of Compugen, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Wednesday, December 10 at 2:10 p.m. ET.
CGEN: 8.27 (+0.14)

Shares of CGEN Down 14.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 02, 5:08PM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 2 months, Compugen has returned 13.96% as of today's recent price of $6.75.
CGEN: 8.27 (+0.14)

Compugen Announces Experimental Confirmation of Additional Methodology for Discovery of Cancer-Related Immune Checkpoints
Business Wire - Tue Dec 02, 6:07AM CST
--Successful initial experimental results reported for drug target candidate identified through new methodology
CGEN: 8.27 (+0.14)

Investors' Radars Failed to Catch Compugen (CGEN), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:54AM CST
Compugen has seen a negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
CGEN: 8.27 (+0.14)

Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen
Brian Coleman - at Seeking Alpha - Fri Nov 21, 11:21AM CST

PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), CGEN: 8.27 (+0.14), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), NVS: 93.52 (-0.82)

Compugen (CGEN) Worth Watching: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:51AM CST
Compugen Ltd. (CGEN) was a big mover last session, as its shares rose nearly 6% on the day.
BIIB: 344.49 (+2.16), ANIP: 54.28 (+2.33), CGEN: 8.27 (+0.14), AMAG: 40.04 (-0.79)

17.1% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Wed Nov 19, 11:19AM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 1 month, Compugen has returned 17.14% as of today's recent price of $6.50.
CGEN: 8.27 (+0.14)

Compugen (CGEN) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:45AM CST
Compugen (CGEN) Enters Oversold Territory
CGEN: 8.27 (+0.14)

Compugen Finance Wins Sustainability Award From Toronto Region Board of Trade
Marketwire Canada - Thu Nov 13, 10:20AM CST
Compugen Finance is proud to have won the Toronto Region Board of Trade's 2014 Business Excellence award for Sustainability. The Award was presented at the Business Excellence Awards Ceremony at Toronto Don Valley Hotel on 6 November 2014.
CGEN: 8.27 (+0.14)

Compugen to Present at Jefferies 2014 Global Healthcare Conference in London
Business Wire - Wed Nov 12, 6:02AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.
CGEN: 8.27 (+0.14)

Should Compugen (CGEN) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:35AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Compugen, the stock of which company has actually seen rising estimates over the past one month.
CGEN: 8.27 (+0.14)

Compugen incurs higher net loss of USD5.4m for Q3 2014
M2 - Thu Oct 30, 6:13AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) stated on Wednesday its net loss of USD5.4m (USD0.11 per diluted share) for the third quarter ending 30 September 2014.
CGEN: 8.27 (+0.14)

Compugen's (CGEN) CEO Anat Cohen-Dayag on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 2:07PM CDT

CGEN: 8.27 (+0.14)

Compugen ups revenues 6% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:04PM CDT

CGEN: 8.27 (+0.14)

Compugen posts 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Wednesday reported a loss of $5.4 million, or 11 cents per share, in its third quarter.
CGEN: 8.27 (+0.14)

Compugen EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:17AM CDT

CGEN: 8.27 (+0.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Envision Tianji Dominates AI Weather Quest, Sets New Bar

Unveiling a Meteorological Masterpiece Envision's Tianji model just took the weather forecasting world by storm, quite literally. This Shanghai-based green tech giant clinched first place in the recent AI Weather Quest organized by the prestigious European Centre for Medium-Range Weather Forecasts (ECMWF). Beating out nearly 20 top-tier teams, Tianji didn't just win—it...

FuelCell Energy Faces Legal Scrutiny After Stock Plunge

FuelCell Energy's Troubling Stock Dive FuelCell Energy's recent plummet isn't just a sobering reality for traders—it comes wrapped in controversy. With NASDAQ:FCEL suffering a 15.69% nosedive after revelations from their fiscal third-quarter results, the ticker’s future hangs precariously. Even for those who've braved the market’s caprices, seeing shares drop $2.68...

Barco Brings HDR Cinema Home with Kinepolis Kortrijk

A New Chapter in Cinema Projection Ah, Belgium, the land of waffles and apparently, cutting-edge cinema tech. That's right, Barco is bringing their HDR by Barco system to its own backyard in Kortrijk, teaming up with Kinepolis to shake things up. It's not just any expansion—it's a homecoming of sorts. The company's laser cinema magic has already made face time in the...

Picturing Grief: Scoville's Visual Journey in Loss

Let Images Speak the Unspeakable So, here's the deal: grief isn't something you can just wrap up in a neat little package of words. It's jagged, messy—and for many, untouchable by a traditional self-help roadmap. Enter Picturing Grief, the book by Michelle Scoville that smashes the mold with its arresting mix of imagery and reflection. Freshly on the scene courtesy of...

GARDANT Expands Reach with International Partnership

GARDANT Global's Strategic Expansion Well, today we saw GARDANT Global make a move that screams ambition. They’re hooking up with International Offset Corporation (IOC) to muscle up their game in the murky waters of government procurement. Why does this matter? Because it's all about who gets the contracts, and with GARDANT’s newfound reach, they’re not just...

Transforming Healthcare Leadership Through Systemic Change

Reframing Physician Leadership for Systemic Transformation Here we go, diving into some serious change-making in the healthcare sphere. If you've ever wandered through a hospital corridor, you've likely felt the tension between docs and the suits. The American Association for Physician Leadership (AAPL) is stirring the pot with a fresh book that might just be the catalyst...

AI Literacy Framework Unfolds at AAC&U Conference

Diverse Institutions Converge on AI Literacy A university conference isn't exactly where you'd expect seismic shifts, but this one's a bit of a dark horse. When big names like University of Phoenix, Boise State, Johns Hopkins, and the Medical University of South Carolina start syncing up their AI strategies, it feels like the sector's quietly brewing something big. At the...

QuidelOrtho's Podcast: AI & Informatics Elevate Labs

Navigating Lab Complexities with QuidelOrtho Who'd have thought a podcast could shake the beakers in a lab? QuidelOrtho Corporation (NASDAQ:QDEL) proves the digital discourse is worth tuning into if you're eyeing diagnostic innovations lately. Episode 62 of their Science Bytes podcast unravels how AI and informatics are shifting gears in laboratory landscapes. The folks...

Keith Strachan Elevates The Master Group's Strategy

Strachan Steps Up as Chief Commercial Officer Keith Strachan is stepping into the role of Chief Commercial Officer at The Master Group—big news up in St-Bruno-de-Montarville. Now, those not neck-deep in HVAC-R might shrug this one off, but for those eyeing the industry, this is where the cards start to shuffle in North America. Master’s shift isn't just paper-pushing;...

VIZ Media Expands Reach with MangaPlaza Partnership

Manga Magic in the Digital Space Another day, another expansion, folks. VIZ Media's latest move to have its manga offerings available on MangaPlaza feels like a pretty shrewd play in the fierce arena of digital content. Who'd have thought decades ago that we'd be sitting here talking about digital comics like they’re the next Netflix? VIZ Media's expansion into...